Dogwood Therapeutics DWTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $13.23M+103% | $6.52M-35.6% | $10.13M-24.4% | $13.4M-23.6% | $17.54M+18.1% | ||
| $15M+78.0% | $8.43M-27.7% | $11.66M-20.7% | $14.7M-23.3% | $19.16M+15.8% | ||
| $12.54K-1.7% | $12.75K-16.6% | $15.29K-5.5% | $16.18K+1.8% | $15.9K-5.4% | ||
| $12.19M-1.7% | $12.4M+1.6% | $12.21M-2.0% | $12.46M+5.4% | $11.82M+0.1% | ||
| $67.83M-1.7% | $68.99M+1.6% | $67.92M-2.0% | $69.3M+5.4% | $65.77M+0.1% | ||
| $95.21M+5.6% | $90.17M-2.0% | $91.99M-4.9% | $96.69M-0.3% | $96.98M+2.8% | ||
| $144.4K-81.0% | $760.95K+30.2% | $584.6K+17.4% | $498.12K-56.8% | $1.15M-6.3% | ||
| $2.56M-16.3% | $3.06M+17.8% | $2.6M+37.7% | $1.89M-26.9% | $2.58M-18.8% | ||
| $14.58M-4.5% | $15.27M+4.6% | $14.61M+3.2% | $14.15M-0.6% | $14.24M-52.6% | ||
| $3.34K+12.3% | $2.97K+1,199% | $229+19.9% | $1910.0% | $191+43.6% | ||
| -$113.06M-4.6% | -$108.08M-3.6% | -$104.3M-17.8% | -$88.55M-4.5% | -$84.74M-14.8% | ||
| $80.62M+7.6% | $74.9M+932% | $7.26M+5.5% | $6.88M-2.9% | $7.09M+170% | ||
| $95.21M+5.6% | $90.17M-2.0% | $91.99M-4.9% | $96.69M-0.3% | $96.98M+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Dogwood Therapeutics's total assets?
- Dogwood Therapeutics (DWTX) holds $95.2M in total assets, down 1.8% year over year.
- How much debt does Dogwood Therapeutics have?
- Dogwood Therapeutics carries $144.9K in total debt against $80.6M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Dogwood Therapeutics have?
- Dogwood Therapeutics holds $13.2M in cash and equivalents.
- Can Dogwood Therapeutics cover its short-term obligations?
- Its current ratio is 5.86 — current assets exceed current liabilities.
- Where does Dogwood Therapeutics's balance sheet data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.